Surface modification of lipid based drug delivery for lungs

The arena of “cancer nanomedicine” has grown significantly in the last 10 years due to advancements in nanotechnology research and development for cancer detection, diagnosis, and treatment. Therapeutic techniques based on nanoparticles have gained popularity because of their ability to selectively target disease areas, efficiently supply hydrophobic medicines, and pierce biological barriers. Currently, formulations based on lipids, metals, magnetic materials, polymers, and branching polymers, and mesoporous silica employ nanocarriers. Due to their special qualities—such as high drug-loading capacity, low toxicity, enhanced bioavailability and biocompatibility, gastrointestinal tract stability, controlled release, streamlined scale-up, and validation process—lipid-based nanocarrier systems have drawn a lot of attention recently. Poor targeting, limited drug encapsulation, and little drug penetration are still problems with nanocarriers. The surface can be changed to lessen these disadvantages. Surface-modified nanocarriers offer accurate pharmaceutical delivery, enhanced penetration efficiency, and controlled release. These kinds of designs allow anticancer gene therapies and chemotherapeutics to be administered to site-specific targets at the same time. In terms of diagnosing, imaging, screening, and treating primary and metastatic lung cancer tumors, treatments based on nanoparticles are setting the standard. But getting such discoveries from the laboratory to the patient's bed has proven to be incredibly challenging due to problems with pharmacology, toxicity, immunology, large-scale production, and regulatory concerns. In this review, we highlight new developments in the management of lung cancer as well as the functionalization of lipid-based nanocarriers by adding fatty acids, polymers, ligands, and surfactants to their surfaces. The literature contained a collection of recently developed lipid-based nanocarrier systems.